Price
$0.268
Decreased by -2.55%
Dollar Volume
278.18 K
ADR%
8.91
Earnings Report Date (estimate)
Mar 28, 23 (-0.23)
Market Cap.
10.88 M
Shares Float
37.41 M
Shares Outstanding
40.61 M
Beta
1.01
Price / Earnings
-0.01
BPR
1.71
20D Range
0.26 0.32
50D Range
0.17 0.32
200D Range
0.17 7.16
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 22 -0.53
Decreased by -165.00%
-0.44
Decreased by -20.45%
Aug 11, 22 -2.71
Decreased by -1.25 K%
-3.70
Increased by +26.76%
Mar 30, 22 -0.20
Increased by 0.00%
-0.15
Decreased by -33.33%
Nov 2, 21 -0.18
Increased by 0.00%
-0.19
Increased by +5.26%
Jul 26, 21 -0.20
Decreased by -66.67%
-0.22
Increased by +9.09%
May 4, 21 -0.20
Decreased by -100.00%
-0.21
Increased by +4.76%
Mar 1, 21 -0.20
Decreased by -100.00%
-0.22
Increased by +9.09%
Nov 12, 20 -0.18
Decreased by -125.00%
-0.18
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 3.00 M
Increased by +133.26%
-19.67 M
Decreased by -17.25%
Decreased by -655.10%
Increased by +49.73%
Jun 30, 22 2.13 M
Increased by +79.41%
-12.22 M
Increased by +30.72%
Decreased by -574.74%
Increased by +61.38%
Mar 31, 22 1.76 M
Increased by +1.42 K%
-11.77 M
Increased by +31.29%
Decreased by -668.31%
Increased by +95.47%
Dec 31, 21 1.51 M
Increased by +102.00%
-23.36 M
Decreased by -32.56%
Decreased by -1.54 K%
Increased by +34.38%
Sep 30, 21 1.29 M
Increased by +N/A%
-16.77 M
Decreased by -8.04%
Decreased by -1.30 K%
Decreased by N/A%
Jun 30, 21 1.19 M
Increased by +N/A%
-17.64 M
Decreased by -62.91%
Decreased by -1.49 K%
Decreased by N/A%
Mar 31, 21 116.00 K
Increased by +N/A%
-17.13 M
Decreased by -117.28%
Decreased by -14.77 K%
Decreased by N/A%
Dec 31, 20 749.00 K
Increased by +N/A%
-17.62 M
Decreased by -192.64%
Decreased by -2.35 K%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.